Der Pathologe

, Volume 38, Issue 6, pp 535–539 | Cite as

Lymphozytäre Myokarditis unter Nivolumabtherapie bei metastasiertem klarzelligen Nierenzellkarzinom

  • R. Sauer
  • P. Kiewe
  • M. Desole
  • M. Schuler
  • F. Theissig
  • A. Roth
  • T. Mairinger
Kasuistiken
  • 189 Downloads

Zusammenfassung

Immunmodulatorische Checkpointinhibitoren gegen das PD-1-Protein gelten als neue Therapieoptionen vieler solider Tumoren. Wir berichten über eine Patientin, die im Rahmen eines metastasierten Nierenzellkarzinoms eine immunmodulatorische Therapie mit Nivolumab erhielt und an den Folgen einer lymphozytären Myokarditis als seltenes immunologisches, therapieassoziiertes Ereignis 2 Wochen nach Therapiebeginn verstarb. Die Todesursache konnte erst durch eine Obduktion geklärt werden. Der Fallbericht verdeutlicht demnach die Wichtigkeit und Notwendigkeit klinischer Sektionen als Instrument zur Qualitätssicherung und Aufklärung therapieassoziierter Nebenwirkungen.

Schlüsselwörter

Nierenzellkarzinom PD-1-Inhibition Immunologisches, therapieassoziiertes Ereignis Lymphozytäre Myokarditis Parvovirus B19 

Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab

Abstract

Immune checkpoint inhibitors against the PD-1 protein offer a new therapy option for many solid cancers. We report a patient with metastatic renal cell cancer treated with Nivolumab. As a rare immune-mediated adverse event, we describe a fatal lymphocytic myocarditis two weeks after starting immune therapy. The cause of death was first diagnosed at autopsy. This case report underlines the importance and need of clinical autopsies as an instrument of quality assurance and detection of rare therapy-induced adverse effects.

Keywords

Renal cell carcinoma PD-1 inhibition Immune-mediated adverse event Lymphocytic myocarditis Parvovirus B19 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

R. Sauer, P. Kiewe, M. Desole, M. Schuler, F. Theissig, A. Roth und T. Mairinger geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004–2012CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Garon EB (2015) Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol 42(Suppl 2):11–18CrossRefGoogle Scholar
  3. 3.
    Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837–1846CrossRefPubMedGoogle Scholar
  4. 4.
    Hodi FS, O’Day SJ, McDermott DF (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    McDermott DF, Drake CG, Sznol M (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving Nivolumab. J Clin Oncol 33:2013–2020CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813CrossRefPubMedGoogle Scholar
  8. 8.
    Mennitto A, Grassi P, Ratta R et al (2016) Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol 8:319–326CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kandolf R (2004) Virusätiologie der inflammatorischen Kardiomyopathie. Dtsch Med Wochenschr 129:2187–2192CrossRefPubMedGoogle Scholar
  10. 10.
    Kuethe F, Lindner J, Matschke K (2009) Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 49:1660–1666CrossRefPubMedGoogle Scholar
  11. 11.
    Nielsen TS, Hansen J, Nielsen LP et al (2014) The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts. Forensic Sci Med Pathol 10:344–350CrossRefPubMedGoogle Scholar
  12. 12.
    Verdonschot J, Hazebroek M, Merken J et al (2016) Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail.  https://doi.org/10.1002/ejhf.665 PubMedGoogle Scholar
  13. 13.
    Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:76–83CrossRefGoogle Scholar
  14. 14.
    Danlos FX (2016) Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149:133–136CrossRefGoogle Scholar
  15. 15.
    Semper H, Muehlberg F, Schulz-Menger J et al (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1 – negative squamous cell carcinoma of the lung. Lung Cancer 99:117–119CrossRefPubMedGoogle Scholar
  16. 16.
    Gibson R, Delaune J, Szady A et al (2016) Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep.  https://doi.org/10.1136/bcr-2016-216228 PubMedGoogle Scholar
  17. 17.
    Läubli H, Balmelli C, Bossard M et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Koelzer VH, Rothschild SI, Zihler D et al (2016) Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 4:13CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J ImmunoTher Cancer 4:50CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Johnson DB, Balko JM, Compton ML et al (2016) Fulminat Myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tarrio ML, Grabie N, Bu DX (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188:4876–4884CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lucas JA, Menke J, Rabacal WA et al (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 181:2513–2521CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang J, Okazaki IM, Yoshida T et al (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22:443–452CrossRefPubMedGoogle Scholar
  24. 24.
    Capelli LC, Shah AA, Bingham CO III (2017) Immune-related adverse effects of cancer immunotherapy – implications for rheumatology. Rheum Dis Clin North Am 43:65–78CrossRefGoogle Scholar
  25. 25.
    Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, acitivity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Koelzer VH, Glatz K, Bubendorf L et al (2017) Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren. Pathologe 38:197–208CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • R. Sauer
    • 1
  • P. Kiewe
    • 2
  • M. Desole
    • 3
  • M. Schuler
    • 3
  • F. Theissig
    • 1
  • A. Roth
    • 1
  • T. Mairinger
    • 1
  1. 1.Institut für PathologieMVZ am HELIOS Klinikum Emil von BehringBerlinDeutschland
  2. 2.MVZ Onkologischer Schwerpunkt am Oskar-Helene-HeimBerlinDeutschland
  3. 3.Klinik für Innere Medizin IIHELIOS Klinikum Emil von BehringBerlinDeutschland

Personalised recommendations